Search

Your search keyword '"Jakrabhandu, Somvilai"' showing total 4 results
Start Over Author "Jakrabhandu, Somvilai"
4 results on '"Jakrabhandu, Somvilai"'

1. A dosimetric comparison of two-phase adaptive intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer.

Author

Chitapanarux, Imjai, Chomprasert, Kittisak, Nobnaop, Wannapa, Wanwilairat, Somsak, Tharavichitkul, Ekasit, Jakrabhandu, Somvilai, Onchan, Wimrak, Traisathit, Patrinee, Van Gestel, Dirk, Chitapanarux, Imjai, Chomprasert, Kittisak, Nobnaop, Wannapa, Wanwilairat, Somsak, Tharavichitkul, Ekasit, Jakrabhandu, Somvilai, Onchan, Wimrak, Traisathit, Patrinee, and Van Gestel, Dirk

Abstract

The purpose of this investigation was to evaluate the potential dosimetric benefits of a two-phase adaptive intensity-modulated radiotherapy (IMRT) protocol for patients with locally advanced nasopharyngeal cancer (NPC). A total of 17 patients with locally advanced NPC treated with IMRT had a second computed tomography (CT) scan after 17 fractions in order to apply and continue the treatment with an adapted plan after 20 fractions. To simulate the situation without adaptation, a hybrid plan was generated by applying the optimization parameters of the original treatment plan to the anatomy of the second CT scan. The dose-volume histograms (DVHs) and dose statistics of the hybrid plan and the adapted plan were compared. The mean volume of the ipsilateral and contralateral parotid gland decreased by 6.1 cm(3) (30.5%) and 5.4 cm(3) (24.3%), respectively. Compared with the hybrid plan, the adapted plan provided a higher dose to the target volumes with better homogeneity, and a lower dose to the organs at risk (OARs). The Dmin of all planning target volumes (PTVs) increased. The Dmax of the spinal cord and brainstem were lower in 94% of the patients (1.6-5.9 Gy, P < 0.001 and 2.1-9.9 Gy, P < 0.001, respectively). The Dmean of the contralateral parotid decreased in 70% of the patients (range, 0.2-4.4 Gy). We could not find a relationship between dose variability and weight loss. Our two-phase adaptive IMRT protocol improves dosimetric results in terms of target volumes and OARs in patients with locally advanced NPC., info:eu-repo/semantics/published

Published
2015

3. Randomized study of nutritional status and treatment toxicities of oral arginine, glutamine, and Omega-3 fatty acids during concurrent chemoradiotherapy for head and neck cancer patients.

Author

Chitapanarux, Imjai, Pisprasert, Veeradej, Tharavichitkul, Ekkasit, Jakrabhandu, Somvilai, Klunklin, Pitchayaponne, Onchan, Wimrak, Supawongwattana, Bongkot, Traisathit, Patrinee, Rattanachaiwong, Sornvichate, and Sattasiri, Witiya M.

Subjects
HEAD & neck cancer treatment, CHEMOTHERAPY complications, CANCER radiotherapy, DIETARY fats, DEGLUTITION disorders, MALNUTRITION risk factors, IMMUNOSUPPRESSION, DISEASE risk factors
Abstract

Background: Patients with head and neck cancer (HNC) undergoing concurrent chemoradiotherapy (CCRT) are at high risk for dysphagia, malnutrition, and immunosuppression. Accordingly, arginine, glutamine, and Omega-3 fatty acidsare immuneenhanced nutrition can promote cellular immunity. We aimed to examine the impact of immunonutrition diet on nutritional status, in addition to CCRT toxicities, within this group of patients. Methods: Forty patients with HNC who were treated with curative CCRT were randomized into group A (n = 20), patients who received a regular diet and dietary counseling by a protocol dietician, and group B (n = 20), patients who received a regular diet plus immuneenhanced nutrition supplements and dietary counseling by the same protocol dietician. Outcome measures were weight loss, protein and energy intake, serum pre-albumin and albumin, and toxicities of CCRT were evaluated at baseline, weekly and at the end of treatment. Results: Both groups were well balanced at baseline. One patient from group A (1/20) withdrew consent. Seven patients from group B (7/20) withdrew from the study; 1 patient could not tolerate the side effect of chemotherapy and 6 patients could not tolerate the taste of oral immune-enhanced nutrition. A significant loss in total body weight was observed in group A patients (p<0.001), whereas in group B there no significant weight loss (p=0.109). Median percentage change from baseline of energy intake was 19.6%, and 22.9% at the end of treatment for group A and B respectively. The circulating levels of nutritional markers, pre-albumin and albumin, decreased after CCRT in both groups. There was a significantly decreased level of albumin in group A compared to that of group B, at the end of treatment. During CCRT; 4 patients (20%) in group A and 1 patient (5%) in group B developed grade 3 mucositis, respectively. One patient (5%) in group A had grade 3 radiation dermatitis. Grade 3-4 hematologic toxicities, mainly in absolute neutrophil count (ANC), were significantly higher in group A than group B: 20% versus 0% (p=0.035). Over the 7-week period of CCRT, both the intention to treat analysis and per protocol analysis revealed similar results in scaled for all endpoints. Conclusions: Nutritional counseling and immuno-nutrition can reduce the deterioration of nutrition status and also significantly reduced hematologic and non-hematologic toxicity of CCRT in head and neck cancer. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results